Valproate for sleep consolidation in periodic limb movement disorder.

Area of Science:

• Neurology
• Sleep Medicine
• Pharmacology

Background:

• Periodic Limb Movement Disorder (PLMD) significantly disrupts sleep and daytime function.
• Current treatments for PLMD may have limitations or side effects.
• Valproate (VPA) is an anticonvulsant with potential applications in sleep disorders.

Purpose of the Study:

• To evaluate the efficacy and long-term effects of valproate (VPA) in treating periodic limb movement disorder (PLMD).
• To assess VPA's impact on sleep parameters and subjective patient outcomes in PLMD.

Main Methods:

• Open-label study involving six adult patients diagnosed with PLMD.
• Polysomnograms (PSGs) were conducted before and after VPA treatment (125-600 mg/night).
• Treatment duration varied from 2 weeks to over a year, with a median follow-up of 5 months.

Main Results:

• All patients reported improved daytime alertness.
• Significant improvements observed in sleep efficiency (76% to 88%, p=0.003).
• Reduced Stage 1 sleep (26% to 13%, p=0.04) and increased deep sleep (Stage 3 & 4: 19% to 30%, p=0.01).

Conclusions:

• Valproate (VPA) demonstrates a beneficial effect on sleep consolidation in patients with PLMD.
• VPA may be a viable long-term treatment option for managing PLMD symptoms.
• Long-term use of VPA in PLMD patients showed sustained benefits with manageable side effects.